Biotech Insider Buying: October 2026 Roundup

Over the last 30 days, 145 insider purchases were filed across 25 biotech companies. These are open-market buys only — we filter out routine 10b5-1 plan transactions, option exercises, and other noise using AI classification. Insider purchases in biotech small-caps carry more signal value than in large-caps, because the information asymmetry is higher. A CEO buying shares 3 weeks before a PDUFA date is making a bet with their own money — and research shows these "opportunistic" purchases predict abnormal returns.

- [KOD](/company/kod) (Kodiak Sciences Inc.): 82 buys totaling $157.0M — Director BAKER BROS. ADVISORS LP at $72.39/share - [AVR](/company/avr) (Anteris Technologies Global Corp.): 5 buys totaling $11.7M — 10% Owner L1 Capital Pty Ltd at $7.51/share - [PRTA](/company/prta) (Prothena Corporation plc): 6 buys totaling $5.8M — 10% Owner SCULLY WILLIAM P at $8.68/share - [INBX](/company/inbx) (Inhibrx Biosciences, Inc.): 6 buys totaling $2.0M — Director Kayyem Jon Faiz at $100.00/share - [XENE](/company/xene) (Xenon Pharmaceuticals Inc.): 2 buys totaling $1.7M — PRESIDENT & CEO MORTIMER IAN at $37.38/share - [HELP](/company/help) (CYBIN INC.): 2 buys totaling $1.4M — Chief Executive Officer Halstead Michael at $13.47/share - [OM](/company/om) (Outset Medical, Inc.): 2 buys totaling $870K — 10% Owner Leonard Braden Michael at $3.53/share - [AGMB](/company/agmb) (Agomab Therapeutics NV): 8 buys totaling $311K — Chief Executive Officer Knotnerus Tim Jasper at $8.48/share - [DMRA](/company/dmra) (Damora Therapeutics, Inc.): 1 buy totaling $253K — Director, President and CEO Jarrett Jennifer at $20.23/share - [NAMSW](/company/namsw) (NewAmsterdam Pharma Co N.V.): 1 buy totaling $227K — Chief Executive Officer Davidson Michael H. at $22.65/share - [TELA](/company/tela) (TELA Bio, Inc.): 4 buys totaling $167K — Director Capper Joseph H at $1.17/share - [TENX](/company/tenx) (TENAX THERAPEUTICS, INC.): 2 buys totaling $111K — Director Doogan Declan at $1.92/share - [HCAT](/company/hcat) (Health Catalyst, Inc.): 1 buy totaling $105K — Chief Executive Officer Kohl Simeon at $1.79/share - [ANNX](/company/annx) (Annexon Biosciences Inc.): 1 buy totaling $100K — PRESIDENT AND CEO Love Douglas at $3.83/share - [ADAG](/company/adag) (Adagene Inc.): 2 buys totaling $70K — Chief Executive Officer Luo Peter at $3.15/share For the full list of filtered insider trades, see the insider signals page.

Not all insider purchases are equal. The strongest signals come from: 1. C-suite executives (CEO, CFO, CMO) rather than 10% institutional owners 2. Open-market purchases rather than option exercises or plan-based transactions 3. Dollar amounts that are material relative to the insider's compensation 4. Timing near catalysts (PDUFA dates, readout windows) where the insider has informational advantage 5. Cluster buys where multiple insiders at the same company buy within a short window BiotechEdge automatically classifies insider transactions and filters out noise so you see only the conviction-driven buys. See our research on Form 4 insider trading for the academic evidence behind this approach. *This article is generated from SEC EDGAR Form 4 filings and does not constitute investment advice.*